LONDON (Reuters) - Japan's Yamanouchi Pharmaceutical Co Ltd said on Monday that U.S. regulators had approved its urinary incontinence drug Vesicare (solifenacin), which will be co-promoted in the United States by GlaxoSmithKline Plc.

The drug is scheduled for launch in the U.S. market in January 2005, following the green light from the Food and Drug Administration, Yamanouchi said in a statement.

The U.S. approval had been expected, following one obtained in Europe where the product was launched in August.

Copyright © 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters Limited. Reuters Limited shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.